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Abstract. The aim of this study was to evaluate whether 
fast trabecular bone loss in osteoporotic and osteopenic pa-
tients can effectively be treated with active vitamin D me-
tabolites. Thirty-one osteoporotic and osteopenic patients 
were monitored between 4 and 22 months before and be-
tween 8 and 18 months during the treatment. Fast bone 
losers were designated as osteoporotic or osteopenic pa-
tients with a loss of trabecular bone density in the radius of 
3% or more calculated for 1 year. For this differentiation, 
the high precise peripheral quantitative computed tomogra-
phy system (DENSISCAN 1000) was used (reproducability 
0.3% in mixed collectives). The pretreatment loss and the 
"gain" under treatment with active vitamin D metabolites 
was calculated for 1 year. The treatment consisted of either 
0.5 flg calcitriol daily or 1 flg of alfacalcidol daily. Before 
treatment, the trabecular bone loss in the radius/year was 
-6.6 ± 0.5% (mean ± SEM). After treatment with vitamin D 
metabolites, the trabecular bone gain in the radius/year was 
0.01 ± 0.6% (mean ± SEM). The difference was highly 
significant (P < 0.001). In contrast to this, the loss of cor-
tical bone density before treatment was -1.8 ± 0.3% (mean 
± SEM) and the reduced loss after treatment -0.2 ± 0.4% 
(mean ± SEM), both values calculated for I year. This dif-
ference was less significant (P < 0.05). This study shows 
that the treatment with active vitamin D metabolites is very 
effective in slowing fast trabecular bone loss in osteoporotic 
and osteopenic patients. 
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In postmenopausal and senile osteoporosis, reduced calcium 
absorption is often reported. Pathophysiologically, a disor-
der in the vitamin D metabolism as cause can be postulated, 
although it is of a different character. For both groups a 
lower concentration of 1,25(OHhD3 in the serum, a de-
crease of the amount of 1,25(OHhD3 receptors, and a dis-
order of the active calcium absorption in the intestine is 
known. For the postmenopausal osteoporosis there is a low 
parathyroid hormone (PTH) level and an additional deficit 
in the activation of the PTH-induced 1,25(OHhD3 synthe-
sis. For the senile osteoporosis, in addition to the above, 
there is a lack of vitamin D uptake and an increase in the 
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amount of cells in the parathyroidea, with a higher level of 
PTH in the serum [1]. 
Vitamin D metabolites have proved to be effective in 
preventing osteoporosis by increasing low mineral density 
[2] and decreasing fracture rates [3-5] while showing a low 
toxicity; the incidence of hypercalcemia is <1 % [6]. The 
prevention of bone loss has been shown to be due to resto-
ration to a positive calcium balance due to a correction of 
calcium malabsorption [7]. Furthermore, it has been re-
ported that treatment with alfacalcidol improves the myop-
athy associated with the bone loss of aging [8] and should 
reduce the tendency to fall and the risk of osteoporotic 
fractures. 
Until now anabolic substances like fluorides were used 
for the tailored treatment of osteoporosis in slow bone losers 
(loss of trabecular bone density in the radius of less than 3% 
calculated for 1 year). Fast bone losers were treated with 
antiresorptive agents like estrogens, calcitonin, and bisphos-
phonates [9]. The aim of the present study was to determine 
whether the treatment with the active vitamin D metabolites 
calcitriol and alfacalcidol can prevent a fast trabecular bone 
loss and could thus be considered as antiresorptive agents. 
Patient and Methods 
Treatment Protocol 
Thirty-one postmenopausal female patients aged 47-82 years were 
admitted to the study. The mean age was 68.1 ± 8.9 years. Patients 
with osteoporosis (trabecular bone density of the radius ~2.5 SD 
of the value of healthy 45-54-year-old normal women [10]) or 
osteopenia (trabecular bone density of the radius 1-2.5 SD) with-
out treatment underwent a follow-up measurement with high pre-
cise peripheral quantitative computed tomography (pQCT) [11] 
not earlier than 4 months after the first measurement. If a trabec-
ular bone loss in the radius of 3% [12] (Fig. I) or more, calculated 
for 1 year was found, the patients were defined as "fast losers" 
and admitted to the study. They underwent a treatment with active 
vitamin D metabolites for 8-18 months. The patients underwent a 
third pQCT measurement not earlier than 8 months after the treat-
ment was started. The measured difference in percentage was 
again calculated for I year. Either 0.5 J,1g calcitriol or 1 J,1g alfa-
calc idol was given daily. 
Bone Densitometry 
The measurements were performed with the pQCT DENSISCAN 
1000 (Scanco, Zurich, Switzerland) [13, 14], which has a repro-
ducibility in mixed collectives of 0.3% [15]. The measuring pro-
cedure can be characterized as foHows. The patient's arm is posi-
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Fig. 1. Individual rate of trabecular bone loss in early postmeno-
pausal women. The number of patients is plotted against the annual 
loss of trabecular bone density. The distribution was bimodal and 
shows a minimum at 3%. This value is taken to separate fast bone 
losers from slow bone losers. 
tioned in a radiolucent cast which enables comfortable immobili-
zation during the measuring process and allows reproducible 
orientation of the bone axis relative to the measuring plane. The 
measuring system-a special-purpose CT instrument for low-dose 
bone densitometry-provides a digital radiogram as a positioning 
aid for the examination site. The examination site in the ultradistal 
radius is then converted with a stack of 10 tomograms (slice thick-
ness I mm, interslice distance 1.5 mm), and the average bone 
density over core volume (D 50) is calculated. This value corre-
sponds to the trabecular bone density (mg/cm3). After the three 
measurements, the bone volume common to all examinations of a 
patient is determined. Then the percentage of trabecular bone den-
sity changes in the radius are evaluated. The radiation dose per 
examination is only 0.1 mSv [12]. Cortical bone density is mea-
sured in the diaphysis from six tomograms (P < 100). 
Statistical Analysis 
The mean and SEM were calculated for the changes in trabecular 
and cortical bone denisty in percentage between the first and the 
second as well as between the second and third pQCT. These 
changes before and after treatment were analyzed with the paired 
Student's t-test. 
Results 
Table 1 summarizes the measured initial values and changes 
in percentage of the trabecular bone density before and after 
treatment. Table 2 shows the same values for the cortical 
bone. The initial value found in the first pQCT for trabec-
ular bone density in the distal radius for all patients was 
133.61 ± 11.86 mg/cm3 (mean ± SEM). This is clearly 
below the bone density of healthy women 45-54 years old 
(255 mg/cm3). 
After 10.13 ± 0.87 (mean ± SEM) months, a second 
pQCT was performed which showed a trabecular bone loss 
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Table 1. Trabecular bone density of the radius: initial value and 
changes in percentage before and after treatment with active vita-
min D metabolites calculated for I year 
Initial value 
(mg/cm3) 
133.6 ± 11.9 
n = 31 
Percentage changes/year 
Before treatment 
-6.6±0.5 P<O.OOI 
Values are mean ± SEM 
After treatment 
+0.01 ±0.6 
Table 2. Cortical bone density of the radius: initial value and 
changes in percentage before and after treatment with active vita-
min D metabolites calculated for I year 
Initial value 
(mg/cm3) 
1101 ± 37 
n = 31 
Percentage changes/year 
Before treatment 
-1.8 ± 0.3 P< 0.05 
Values are mean ± SEM 
After treatment 
-0.2 ± 0.4 
in the peripheral radius of -6.61 ± 0.52% (mean ± SEM) 
and the cortical bone loss of -1.76 ± 0.34% (mean ± SEM) 
calculated for I year. After undergoing a treatment with 
either calcitriol or alfacalcidol for 12.13 ± 0.43 (mean ± 
SEM) months, the third pQCT was performed. It showed a 
trabecular bone gain of + 0.01 ± 0.59% (mean ± SEM) and 
a reduced loss of cortical bone of -0.24 ± 0.39% (mean ± 
SEM) calculated for I year (Figs. 2 and 3). Analyzing the 
values before and after treatment with the paired Student's 
t-test, a highly significant difference for trabecular bone 
could be found (P < 0.001). For cortical bone, the difference 
was less significant (P < 0.05). 
Discussion 
The active vitamin D metabolites calcitriol (0.5 flg/daily) 
and alfacalcidol (I flg/daily) have been found to be highly 
effective in the treatment of fast trabecular bone loss in 
osteoporotic and osteopenic patients. We have shown that 
this treatment did not only stop the loss of trabecular bone 
density in the peripheral radius measured with the high pre-
cise pQCT but there was a gain of density in several pa-
tients. The cortical bone density loss was at least signifi-
cantly reduced. The radius as a nonweight-bearing bone is 
less sensitive to changes in mobility habits of the patient. 
The trabecular bone density of the radius seems to be the 
most reliable parameter for an osteoporosis follow-up be-
cause it reflects the bone turnover. 
The therapy consisted of either 0.5 flg of calcitriol daily, 
the active kidney metabolite of I flg alfacalcidol daily. The 
la-hydroxyvitamin D3 (la-(OH)D3) is a pro-drug which is 
hydroxylated in the liver and bone into the active 1,25-
dihydroxyvitamin D3 [3]. The dose of 0.5 flg calcitriol is 
equivalent to 1 flg alfacalcidol. 
Vitamin D metabolites have been proven in this study to 
be antiresorptive, active agents in fast-losing osteoporosis. 
The mechanisms through which this occurs are reported to 
be (I) increasing the active vitamin D metabolites in the 
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Fig. 2. Trabecular bone loss of the distal radius in percentages 
(calculated for I year) before and after treatment (P < 0.001). 
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Fig. 3. Cortical bone loss of the radius in percentages (calculated 
for I year) before and after treatment (P < 0.05). 
serum and the bone that are low due to a lower production 
in the kidney (lack of la-hydroxylase) and the bone [16]; 
(2) facing the vitamin D resistance due to the lack of 
1,25(OH)zD3 receptors in the intestine and the bone [17, 
18]; (3) facing the effect of the senile secondary hyperpara-
thyroidism [19] due to the increase of cell number in the 
parathyroid gland [20]; (4) reducing the increase of cyto-
kines (IL-l, IL-6) induced by the postmenopausal estrogen 
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deficiency [21, 22]. In addition, the increase of PTH causes 
decreased coupled bone formation [23] which is due to 
changes of the insulin-like growth factor (IGF) system. PTH 
induces a higher production of binding protein 4 (IGFBP4) 
which neutralizes the anabolic effect of IGF. 
Active vitamin D metabolites can replace the currently 
used antiresorptive agents such as estrogens, calcitonin, and 
bisphosphonates thanks to their high efficacy, low toxicity, 
and less side effects [24]. In the study's collective, no severe 
hypercalcemia was found; the highest measured value under 
treatment was 2.48 mmol/liter (upper normal value 2.42 
mmollliter). This is due to the controlled amount of oral 
calcium intake which is reported to be 600-800 mg per day 
[25]. Moreover, a considerable number of our patients have 
reported an increase in general well-being and a decrease of 
pain. None of the patients suffered severe dizziness. Only a 
few patients have reported intestinal problems such as stom-
ach pain or diarrhea. These problems could always be 
solved by interrupting the treatment for about 2 weeks and 
restarting it in splitted dose of, e.g., two times 0.25 ,..,.,g 
calcitriol 2x/day. 
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